HK1004396A1 - Compounds and methods for the treatment of cardiovascular, inflammatory and immune disorders. - Google Patents

Compounds and methods for the treatment of cardiovascular, inflammatory and immune disorders.

Info

Publication number
HK1004396A1
HK1004396A1 HK98103657A HK98103657A HK1004396A1 HK 1004396 A1 HK1004396 A1 HK 1004396A1 HK 98103657 A HK98103657 A HK 98103657A HK 98103657 A HK98103657 A HK 98103657A HK 1004396 A1 HK1004396 A1 HK 1004396A1
Authority
HK
Hong Kong
Prior art keywords
lipoxygenase
compounds
inflammatory
activity
acting
Prior art date
Application number
HK98103657A
Other languages
English (en)
Inventor
Xiong Cai
Gurmit Grewal
Sajjjat Hussoin
Aberra Fura
Ralph Scannell
Tesfaye Biftu
Changgeng Qian
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/265,656 external-priority patent/US5792776A/en
Priority claimed from US08/390,641 external-priority patent/US6201016B1/en
Priority claimed from US08/454,600 external-priority patent/US5750565A/en
Priority claimed from US08/454,748 external-priority patent/US5703093A/en
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Publication of HK1004396A1 publication Critical patent/HK1004396A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/10—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/14—Radicals substituted by nitrogen atoms not forming part of a nitro radical

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cardiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK98103657A 1994-06-27 1998-04-29 Compounds and methods for the treatment of cardiovascular, inflammatory and immune disorders. HK1004396A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US08/265,656 US5792776A (en) 1994-06-27 1994-06-27 Compounds and methods for the treatment of cardiovascular, inflammatory and immune disorders
US08/390,641 US6201016B1 (en) 1994-06-27 1995-02-17 Compounds and methods for the treatment of cardiovascular, inflammatory and immune disorders
US08/454,600 US5750565A (en) 1995-05-25 1995-05-25 Compounds and methods for the treatment of cardiovascular, inflammatory and immune disorders
US08/454,748 US5703093A (en) 1995-05-31 1995-05-31 Compounds and methods for the treatment of cardiovascular, inflammatory and immune disorders
PCT/US1995/008213 WO1996000212A1 (en) 1994-06-27 1995-06-27 Compounds and methods for the treatment of cardiovascular, inflammatory and immune disorders

Publications (1)

Publication Number Publication Date
HK1004396A1 true HK1004396A1 (en) 1998-11-27

Family

ID=27500861

Family Applications (1)

Application Number Title Priority Date Filing Date
HK98103657A HK1004396A1 (en) 1994-06-27 1998-04-29 Compounds and methods for the treatment of cardiovascular, inflammatory and immune disorders.

Country Status (18)

Country Link
EP (1) EP0770064B1 (de)
KR (1) KR100276570B1 (de)
CN (1) CN1151125C (de)
AT (1) ATE253564T1 (de)
AU (1) AU703756B2 (de)
BR (1) BR9508196A (de)
CA (1) CA2194064C (de)
CZ (1) CZ372096A3 (de)
DE (1) DE69532077T2 (de)
EE (1) EE9600184A (de)
FI (1) FI965123A (de)
HK (1) HK1004396A1 (de)
HU (1) HUT77773A (de)
MX (1) MX9606635A (de)
NO (1) NO965569L (de)
PL (1) PL317873A1 (de)
RU (1) RU2190607C2 (de)
WO (1) WO1996000212A1 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5463083A (en) 1992-07-13 1995-10-31 Cytomed, Inc. Compounds and methods for the treatment of cardiovascular, inflammatory and immune disorders
PT650485E (pt) 1992-07-13 2001-03-30 Millennium Pharm Inc 2,5-diaril-tetra-hidro-tiofenos -furanos e analogos para o tratamento de desordens inflamatorias e imunitarias
US5434151A (en) * 1992-08-24 1995-07-18 Cytomed, Inc. Compounds and methods for the treatment of disorders mediated by platelet activating factor or products of 5-lipoxygenase
US6201016B1 (en) 1994-06-27 2001-03-13 Cytomed Incorporated Compounds and methods for the treatment of cardiovascular, inflammatory and immune disorders
US5750565A (en) 1995-05-25 1998-05-12 Cytomed, Inc. Compounds and methods for the treatment of cardiovascular, inflammatory and immune disorders
US5703093A (en) * 1995-05-31 1997-12-30 Cytomed, Inc. Compounds and methods for the treatment of cardiovascular, inflammatory and immune disorders
US5792776A (en) * 1994-06-27 1998-08-11 Cytomed, Inc., Compounds and methods for the treatment of cardiovascular, inflammatory and immune disorders
WO1999049865A1 (en) * 1998-03-31 1999-10-07 Mayo Foundation For Medical Education And Research Use of platelet activating factor (paf) inhibitors to inhibit il-5 induced eosinophil activation or degranulation
US6310221B1 (en) 1998-07-03 2001-10-30 Millennium Pharmaceuticals, Inc. Methods for synthesis of substituted tetrahydrofuran compound
EP1094805A4 (de) * 1998-07-03 2002-08-28 Millennium Pharm Inc Alicyclische verbindungen mit substituiertem sauerstoffatom, sowie deren bereitungsverfahren
US6255498B1 (en) 1998-10-16 2001-07-03 Millennium Pharmaceuticals, Inc. Method for synthesizing diaryl-substituted heterocyclic compounds, including tetrahydrofurans
ES2381775T3 (es) 2000-08-04 2012-05-31 Dmi Biosciences, Inc. Procedimiento del uso de dicetopiperazinas y composición que las contiene
ATE479683T1 (de) 2002-11-05 2010-09-15 Glaxo Group Ltd Antibakterielle mittel
EP2799114A3 (de) 2003-05-15 2015-02-18 Ampio Pharmaceuticals, Inc. Behandlung von T-Zellen-vermittelten Krankheiten
JP5856843B2 (ja) 2008-05-27 2016-02-10 アンピオ ファーマシューティカルズ，インコーポレイテッド ジケトピペラジンを用いた医薬組成物
WO2012033792A2 (en) 2010-09-07 2012-03-15 Dmi Acquisition Corp. Treatment of diseases
MY167804A (en) 2011-10-10 2018-09-26 Ampio Pharmaceuticals Inc Treatment of degenerative joint disease
MX2014003856A (es) 2011-10-10 2015-01-16 Ampio Pharmaceuticals Inc Dispositivos medicos implantables con tolerancia inmune incrementada y metodos para hacerlos e implantarlos.
EP2771007B1 (de) 2011-10-28 2018-04-04 Ampio Pharmaceuticals, Inc. Behandlung von rhinitis
JP6588005B2 (ja) 2013-03-15 2019-10-09 アンピオ ファーマシューティカルズ，インコーポレイテッド 軟骨形成を刺激するために使用される医薬組成物
KR101503647B1 (ko) 2014-07-03 2015-03-18 주식회사 큐리언트 염증성 질환 치료용 약학적 조성물
KR101480674B1 (ko) * 2014-07-03 2015-01-09 주식회사 큐리언트 화합물 및 염증성 질환 치료용 약학적 조성물
KR101496094B1 (ko) 2014-07-04 2015-02-25 주식회사 큐리언트 화합물 및 염증성 질환 치료용 약학적 조성물
KR101496095B1 (ko) * 2014-07-04 2015-03-03 주식회사 큐리언트 화합물 및 염증성 질환 치료용 약학적 조성물
KR101496096B1 (ko) * 2014-07-17 2015-03-02 주식회사 큐리언트 화합물 및 염증성 질환 치료용 약학적 조성물
RU2736513C2 (ru) 2014-08-18 2020-11-17 Ампио Фармасьютикалз, Инк. Лечение патологических состояний суставов
US11389512B2 (en) 2015-06-22 2022-07-19 Ampio Pharmaceuticals, Inc. Use of low molecular weight fractions of human serum albumin in treating diseases

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4757084A (en) * 1984-02-29 1988-07-12 Merck & Co., Inc. 2,5-diaryl tetrahydrothiophenes and analogs thereof as PAF-antagonists
NZ211146A (en) * 1984-02-29 1987-10-30 Merck & Co Inc 2,5-diaryl-tetrahydrothiophene derivatives and pharmaceutical compositions
US4604407A (en) * 1985-04-04 1986-08-05 E. R. Squibb & Sons, Inc. Hydroxamates
EP0257921B1 (de) * 1986-08-21 1992-04-15 Merck & Co. Inc. 1,3-Diarylcyclopentane und deren Abkömmlinge als PAF-Antagonisten
US4873259A (en) * 1987-06-10 1989-10-10 Abbott Laboratories Indole, benzofuran, benzothiophene containing lipoxygenase inhibiting compounds
US4996203A (en) * 1987-12-21 1991-02-26 Merck & Co., Inc. 2,5-diaryl tetrahydrofurans and analogs thereof as PAF antagonists
EP0365089A3 (de) * 1988-10-18 1991-06-05 Merck & Co. Inc. 2-Aryl-5(3-methoxy-5-(hydroxypropylsulfonyl)-4-propoxyphenyl)tetrahydrothiophen und Analoge
US5175183A (en) * 1989-02-01 1992-12-29 Abbott Laboratories Lipoxygenase inhibiting compounds
US4977146A (en) * 1989-06-08 1990-12-11 Merck & Co., Inc. 2,5-diaryl tetrahydrofurans and analogs thereof as PAF antagonists
US5037853A (en) * 1989-12-28 1991-08-06 Abbott Laboratories Cyclopropyl derivative lipoxygenase inhibitors
GB9009469D0 (en) * 1990-04-27 1990-06-20 British Bio Technology Compounds
EP0465122A1 (de) * 1990-06-29 1992-01-08 Merck & Co. Inc. Verfahren zur Herstellung von 2,5-Diaryl-tetrahydrofuranen und deren Analogen, welche als PAF-Antagonisten verwendbar sind
US5244896A (en) * 1990-09-14 1993-09-14 Marion Merrell Dow Inc. Carbocyclic adenosine analogs useful as immunosuppressants
US5110831A (en) * 1990-11-30 1992-05-05 Du Pont Merck Pharmaceutical Company Vinylogous hydroxamic acids and derivatives thereof as 5-lipoxygenase inhibitors
JPH0730061B2 (ja) * 1991-02-07 1995-04-05 ファイザー製薬株式会社 ヒドロキサム酸誘導体および組成物
US5420164A (en) * 1991-04-04 1995-05-30 Yoshitomi Pharmaceutical Industries, Ltd. Cycloalkylurea compounds
US5183818A (en) * 1991-08-27 1993-02-02 Abbott Laboratories Arylalkylether and arylalkylthioether inhibitors of lipoxygenase enzyme activity
US5169854A (en) * 1992-02-26 1992-12-08 Abbott Laboratories N-substituted-furylalkenyl hydroxamic acid and N-hydroxyurea compounds having lipoxygenase inhibitory activity
US5187192A (en) * 1992-03-13 1993-02-16 Abbott Laboratories Cyclobutyl derivatives having lipoxygenase inhibitory activity
US5326787A (en) * 1992-05-12 1994-07-05 Abbott Laboratories Cycloalkyl N-hydroxy derivatives having lipoxygenase inhibitory activity
US5463083A (en) * 1992-07-13 1995-10-31 Cytomed, Inc. Compounds and methods for the treatment of cardiovascular, inflammatory and immune disorders
PT650485E (pt) * 1992-07-13 2001-03-30 Millennium Pharm Inc 2,5-diaril-tetra-hidro-tiofenos -furanos e analogos para o tratamento de desordens inflamatorias e imunitarias
US5288751A (en) * 1992-11-06 1994-02-22 Abbott Laboratories [(Substituted) phenyalkyl]furylalkynyl-and [substituted) phenyalkyl] thienylalkynyl-N-hydroxyurea inhibitors or leukotriene biosynthesis
TW448144B (en) * 1993-08-19 2001-08-01 Pfizer Phenoxyphenyl cyclopentenyl hydroxyureas

Also Published As

Publication number Publication date
WO1996000212A1 (en) 1996-01-04
RU2190607C2 (ru) 2002-10-10
NO965569L (no) 1997-02-17
AU703756B2 (en) 1999-04-01
EP0770064A4 (de) 1998-01-14
PL317873A1 (en) 1997-04-28
BR9508196A (pt) 1997-09-02
EP0770064B1 (de) 2003-11-05
FI965123A0 (fi) 1996-12-19
DE69532077D1 (de) 2003-12-11
NO965569D0 (no) 1996-12-23
EP0770064A1 (de) 1997-05-02
CN1163610A (zh) 1997-10-29
AU2914295A (en) 1996-01-19
DE69532077T2 (de) 2004-09-02
HUT77773A (hu) 1998-08-28
EE9600184A (et) 1997-06-16
KR100276570B1 (ko) 2001-02-01
MX9606635A (es) 1997-12-31
HU9603611D0 (en) 1997-02-28
CA2194064C (en) 2009-03-17
CA2194064A1 (en) 1996-01-04
FI965123A (fi) 1997-02-26
ATE253564T1 (de) 2003-11-15
CN1151125C (zh) 2004-05-26
CZ372096A3 (cs) 1998-04-15

Similar Documents

Publication Publication Date Title
HU9603611D0 (en) Compounds and methods for the treatment of cardiovascular, inflammatory and immune disorders
EP0766676A4 (de) Verbindungen und verfahren zur hemmung von phosphodiesrerase iv
MY133647A (en) Substituted quinoline-2-carboxamides, their preparation and their use as pharmaceuticals, and intermediates
EP0785927A4 (de) Neue benzoxazole
PL319785A1 (en) Pharmaceutic compositions for treating diseases caused by production of il-6
CA2272584A1 (en) Novel substituted pyrazole derivatives for the treatment of cardiocirculatory diseases
NZ235155A (en) Peptidase substrates in which the carboxy terminal group has been replaced by a tricarbonyl radical
HUP0001539A2 (hu) 2-(1-Imino-etil-amino)-etil-homocisztein, eljárás előállítására és az ezt tartalmazó gyógyszerkészítmények
WO1993000330A3 (en) Azanorbornane derivatives
NO20060719L (no) Substituerte cykloalkylaminderivater som modulatorer av kemokin reseptor aktivitet
AU1996301A (en) Novel heteroaryl-diazabicycloalkanes
WO2003037368A3 (en) Smad7 inhibitors for the treatment of cns diseases
ES2087038A1 (es) Nuevas piperidinas con actividad antagonista del paf.
GR3035063T3 (en) 2,5-diaryl tetrahydro-thiophenes, -furans and analogs for the treatment of inflammatory and immune disorders.
NO974320L (no) Fucopeptider
HK1018265A1 (en) Piperazino derivatives as neurokinin antagonists
MX9708416A (es) Derivados de piperazino como antagonistas de neuroquininas.
NO20060112L (no) Imidazolderivater III
AR020327A1 (es) Uso de una cantidad terapeuticamente efectiva de (-)norcisaprida, o una sal farmacologicamente aceptable de la misma, sustancialmente libre de su (+)estereoisomero, para la preparacion de medicamentos.
WO2003095967A3 (en) Diagnostics and therapeutics for diseases associated with chemokine receptor 9(ccr9)
CA2394230A1 (en) Novel stromelysin inhibitors
HUP0204116A3 (en) Methods of treating short stature disorders related to the short stature homeobox-containing (shox) gene
WO2004056821A3 (en) Quinolizidine derivatives
WO2004042405A3 (en) Diagnostics and therapeutics for diseases associated with human g-protein coupled receptor 3 (gpr3)
WO2004057328A3 (en) Diagnostics and therapeutics for diseases associated with g-protein-coupled receptor 38 (gpr38)

Legal Events

Date Code Title Description
AS Change of ownership

Owner name: MILLENNIUM PHARMACEUTICALS, INC.

Free format text: FORMER OWNER(S): CYTOMED, INC

PE Patent expired

Effective date: 20150626